Please Scroll Down to See Forums Below
Side Effects of Bromoctopine?
- Thread starter Parabola
- Start date
Bromocriptine (Parlodel)
Adverse Effects
During the first days of treatment, some patients may experience mild nausea and, less frequently, dizziness, fatigue or vomiting. However these side effects have never been of such an intensity as to require a suppression of treatment.
In rare cases, PARLODEL may lead to a lowering of blood pressure. For this reason supervision and evaluations of out-patients are advisable during the early days of treatment. Should such undesired side effects persist, the dosage should be reduced.
Reversible pallor in fingers and toes caused by cold should be reported in the case of patients undergoing a prolonged treatment of 20 mg and more, especially in patients who have previously suffered from Raynaud's phenomenon.
There have also been cases of vasospasm, hallucinations and confusion, hypotension and diskinesia.
Constipation, drowsiness and, less frequently, psychomotor excitation, leanness of the jaw and leg cramp have also been reported during treatment of Parkinson's disease with PARLODEL.
At times certain dose-dependent effects may be controlled by a lowering of the dosage. Postural hypotension may be unpleasant but can be treated symptomatically.
If, after taking this pharmaceutical product, the patient notes unpleasant side effects which are not described in this leaflet, he should consult his family doctor.
Precautions
In patients with galactorrhoea and prolactin-dependent amenorrhoea, menstrual disorders or acromegaly, PARLODEL may eliminate pre-existing sterility. Women who may become fertile but who do not wish to conceive should therefore adopt a mechanical form of contraception. The exact cause of infertility should be determined before beginning PARLODEL treatment.
Pregnancy should be avoided if hypophysial adenoma has been diagnosed. A marked lengthening of the sella turcica or a defect in the field of vision requires, first of all, surgery or radiotherapy. PARLODEL is only recommended should these measures fail. In the absence of hypophysial adenoma and should the patient be anxious to conceive, PARLODEL treatment should be stopped as soon after conception as possible (early pregnancy diagnosis with immunological test) since knowledge of the possible effects of this pharmaceutical product on the development of pregnancy and the fetus is as yet inconclusive. As a precautionary measure in the case of confirmed pregnancy, the possible negative effects of a pathological hypophysial problem associated with the pregnancy should be controlled regularly (for example, checking the field of vision).
Sporadic gastrointestinal bleeding has been known to occur in patients with acromegaly, whether they are undergoing PARLODEL treatment, another treatment, or no treatment at all. Until more complete information is available, it is thus preferable for acromegaly patients with case-histories of peptic ulcer to receive some other form of treatment. If it is essential that such patients take PARLODEL, they can soon expect signs of such gastroenteric reactions.
Caution is advised when PARLODEL is taken in large doses by patients suffering from Parkinson's disease with case histories of psychotic disorders, serious cardiovascular problems, peptic ulcers or gastroenteric bleeding.
Some cases of pleural effusions have been reported in Parkinson patients undergoing long-term high-dosage PARLODEL treatment. Although the causal correlation between PARLODEL and these reports has not been proved, it is still advisable for patients who show inexplicable pleuro-pulmonary signs or symptoms to be examined and the possibility of stopping PARLODEL treatment considered.
Interactions With Other Medicines
The possibility of interactions between bromocriptine and psychoactive or hypotensive drugs should not be ruled out. Particular caution should be taken with regard to patients undergoing treatment with ergot alkaloids or products which might possibly increase arterial pressure.
Special Warning
For instructions as to the use of this product during pregnancy or by patients with acromegaly and/or hypophysial adenoma, see "PRECAUTIONS". Treatment must be carried out under medical supervision, including hormone dosage and gynaecological consultation. All women being treated with PARLODEL for a continuous period of longer than 6 months should have gynaecological check-ups once a year if they have not reached menopause, and every 6 months if they are undergoing menopause (with cervical and if possible endometrial cytology). Women with affections not linked to hyperprolactaemia should take the lowest possible effective dosage of PARLODEL to alleviate the symptoms, so as to avoid the possibility of lowering the prolactin level below normal with a consequent alteration of the luteinic function. Tests concerning plasmatic prolactin and post-ovulatory progesterone should be carried out on such patients if treatment is prolonged for longer than 6 months. In the event of hypotensive reactions, which can occur with certain patients especially during the first days of treatment, particular care should be taken when driving or operating machinery.
Directions For Use
This product is always to be taken at mealtimes. Galactorrhoea and/or prolactin-dependent amenorrhoea, hyperprolactaemic infertility: half a tablet 3 times daily. If this is not sufficient, increase the dosage gradually to 1 tablet, 2-3 times daily with meals. Continue the treatment until the mammary secretion disappears completely, and, should the problem be compounded by amenorrhoea, until the menstrual cycle returns to normal. The treatment may be continued if necessary for several menstrual cycles in order to avoid a relapse. Disorders of the menstrual cycle:- Pre-menstrual syndrome. Begin treatment on the 14th day of the menstrual cycle with a half tablet per day, then gradually increase the dosage by half a tablet until reaching the dosage of 1 tablet twice daily. Continue this treatment until the onset of the menstrual flow.
Brief luteinic phase. Half a tablet 3 times daily, gradually increasing the dosage to 1 tablet twice daily with meals until the luteinic phase has returned to normal.
Male hypogonadism: half a tablet 3 times daily, gradually increasing to 1 tablet 3 times daily for a period of 2-3 months.
Acromegaly: Start by taking 1 tablet per day, gradually increasing the dosage over 1-2 weeks to 4-8 tablets, according to the patient's needs, clinical response and tolerance. The daily dosage should be divided into 4 separate and equal doses.
Parkinson's disease: The effects of Parkinson's disease can be combated with low doses, 10-15 mg daily. The effective therapeutic dosage when PARLODEL is taken alone is usually high (30 mg or more per day).
However, if PARLODEL is taken together with L-dopa, with or without the dopa-decarboxylase inhibitor, a lower dosage may suffice. The recommended initial dosage is 2.5 mg twice a day (at mealtimes) for a week. The dosage increase must be gradual and regular: normally not by more than 5 mg every 2-3 days in the initial phase of treatment. Later on, the final dosage increase can be done gradually, not more than 10 mg at a time, depending on therapeutic response and tolerance. Similarly, each reduction of the L-dopa dosage must be gradual until optimum results are obtained. In certain cases L-dopa treatment may be stopped altogether.
Adverse Effects
During the first days of treatment, some patients may experience mild nausea and, less frequently, dizziness, fatigue or vomiting. However these side effects have never been of such an intensity as to require a suppression of treatment.
In rare cases, PARLODEL may lead to a lowering of blood pressure. For this reason supervision and evaluations of out-patients are advisable during the early days of treatment. Should such undesired side effects persist, the dosage should be reduced.
Reversible pallor in fingers and toes caused by cold should be reported in the case of patients undergoing a prolonged treatment of 20 mg and more, especially in patients who have previously suffered from Raynaud's phenomenon.
There have also been cases of vasospasm, hallucinations and confusion, hypotension and diskinesia.
Constipation, drowsiness and, less frequently, psychomotor excitation, leanness of the jaw and leg cramp have also been reported during treatment of Parkinson's disease with PARLODEL.
At times certain dose-dependent effects may be controlled by a lowering of the dosage. Postural hypotension may be unpleasant but can be treated symptomatically.
If, after taking this pharmaceutical product, the patient notes unpleasant side effects which are not described in this leaflet, he should consult his family doctor.
Precautions
In patients with galactorrhoea and prolactin-dependent amenorrhoea, menstrual disorders or acromegaly, PARLODEL may eliminate pre-existing sterility. Women who may become fertile but who do not wish to conceive should therefore adopt a mechanical form of contraception. The exact cause of infertility should be determined before beginning PARLODEL treatment.
Pregnancy should be avoided if hypophysial adenoma has been diagnosed. A marked lengthening of the sella turcica or a defect in the field of vision requires, first of all, surgery or radiotherapy. PARLODEL is only recommended should these measures fail. In the absence of hypophysial adenoma and should the patient be anxious to conceive, PARLODEL treatment should be stopped as soon after conception as possible (early pregnancy diagnosis with immunological test) since knowledge of the possible effects of this pharmaceutical product on the development of pregnancy and the fetus is as yet inconclusive. As a precautionary measure in the case of confirmed pregnancy, the possible negative effects of a pathological hypophysial problem associated with the pregnancy should be controlled regularly (for example, checking the field of vision).
Sporadic gastrointestinal bleeding has been known to occur in patients with acromegaly, whether they are undergoing PARLODEL treatment, another treatment, or no treatment at all. Until more complete information is available, it is thus preferable for acromegaly patients with case-histories of peptic ulcer to receive some other form of treatment. If it is essential that such patients take PARLODEL, they can soon expect signs of such gastroenteric reactions.
Caution is advised when PARLODEL is taken in large doses by patients suffering from Parkinson's disease with case histories of psychotic disorders, serious cardiovascular problems, peptic ulcers or gastroenteric bleeding.
Some cases of pleural effusions have been reported in Parkinson patients undergoing long-term high-dosage PARLODEL treatment. Although the causal correlation between PARLODEL and these reports has not been proved, it is still advisable for patients who show inexplicable pleuro-pulmonary signs or symptoms to be examined and the possibility of stopping PARLODEL treatment considered.
Interactions With Other Medicines
The possibility of interactions between bromocriptine and psychoactive or hypotensive drugs should not be ruled out. Particular caution should be taken with regard to patients undergoing treatment with ergot alkaloids or products which might possibly increase arterial pressure.
Special Warning
For instructions as to the use of this product during pregnancy or by patients with acromegaly and/or hypophysial adenoma, see "PRECAUTIONS". Treatment must be carried out under medical supervision, including hormone dosage and gynaecological consultation. All women being treated with PARLODEL for a continuous period of longer than 6 months should have gynaecological check-ups once a year if they have not reached menopause, and every 6 months if they are undergoing menopause (with cervical and if possible endometrial cytology). Women with affections not linked to hyperprolactaemia should take the lowest possible effective dosage of PARLODEL to alleviate the symptoms, so as to avoid the possibility of lowering the prolactin level below normal with a consequent alteration of the luteinic function. Tests concerning plasmatic prolactin and post-ovulatory progesterone should be carried out on such patients if treatment is prolonged for longer than 6 months. In the event of hypotensive reactions, which can occur with certain patients especially during the first days of treatment, particular care should be taken when driving or operating machinery.
Directions For Use
This product is always to be taken at mealtimes. Galactorrhoea and/or prolactin-dependent amenorrhoea, hyperprolactaemic infertility: half a tablet 3 times daily. If this is not sufficient, increase the dosage gradually to 1 tablet, 2-3 times daily with meals. Continue the treatment until the mammary secretion disappears completely, and, should the problem be compounded by amenorrhoea, until the menstrual cycle returns to normal. The treatment may be continued if necessary for several menstrual cycles in order to avoid a relapse. Disorders of the menstrual cycle:- Pre-menstrual syndrome. Begin treatment on the 14th day of the menstrual cycle with a half tablet per day, then gradually increase the dosage by half a tablet until reaching the dosage of 1 tablet twice daily. Continue this treatment until the onset of the menstrual flow.
Brief luteinic phase. Half a tablet 3 times daily, gradually increasing the dosage to 1 tablet twice daily with meals until the luteinic phase has returned to normal.
Male hypogonadism: half a tablet 3 times daily, gradually increasing to 1 tablet 3 times daily for a period of 2-3 months.
Acromegaly: Start by taking 1 tablet per day, gradually increasing the dosage over 1-2 weeks to 4-8 tablets, according to the patient's needs, clinical response and tolerance. The daily dosage should be divided into 4 separate and equal doses.
Parkinson's disease: The effects of Parkinson's disease can be combated with low doses, 10-15 mg daily. The effective therapeutic dosage when PARLODEL is taken alone is usually high (30 mg or more per day).
However, if PARLODEL is taken together with L-dopa, with or without the dopa-decarboxylase inhibitor, a lower dosage may suffice. The recommended initial dosage is 2.5 mg twice a day (at mealtimes) for a week. The dosage increase must be gradual and regular: normally not by more than 5 mg every 2-3 days in the initial phase of treatment. Later on, the final dosage increase can be done gradually, not more than 10 mg at a time, depending on therapeutic response and tolerance. Similarly, each reduction of the L-dopa dosage must be gradual until optimum results are obtained. In certain cases L-dopa treatment may be stopped altogether.
SonnyBlack
New member
the one side effect thta i found to be most promounced was the fatigue....it made me tired all day long...well ive only taken it for like one week staright but apparently they say that the side effects go away after a couple of weeks of continued usage. I never got any of the nausea that some people say they do...oh yea and i also got the headaches.
SonnyBlack
New member
Parabola said:
dude..i tried everything for my puffy nips....from yohimburn to Liquidex...and i really got no effects from it...but ever since i tried Bromo...my puffy nips have gone down a whole lot....like a whole lot...i guess it really just depends on whether your problem is estrogen related or prolactin related. At first i thought mie was estrogen related but it wasnt....
SonnyBlack
New member
oh yea...dont take it before going on a plane..it causes nausea sometimes. I took it on the plane on my last trip to vegas and i felt like shit too....i felt nauseous and strangely very nervous...
WannaImpress
New member
SonnyBlack, what dosage are you taking of Bromo., are you taking it to combat prolactin? I'm interested to know because I was on a Test/Tren cycle when I started to get puffy/sore nipples and have some lactating and I don't think it was from the Test sinc I was taking a 1/4 cc a day. I received my Bromo. and curious on how much you guys recommend along with some vitex?
Hugh Gellatts
New member
just try alot of vitex first. any drug that messes with dopamine as much as bromo is gonna make you feel weird, especially when you first start.
Tx for Gyno
Bromocriptine is a dopamine(DA) agonist as is Pardolel. The DA and Prolactin endocrine connection is where these drugs work. Bromo is currently FDA approved for prolactin induced gyno. Now if you were having negative feedback upon your pituitary as is the situation on a cycle your Prolactin levels would most likely be low, but I have no evidence of that, it is just my medical opinion. in other words you need something that works at the receptors in your breast tissue.
Bromocriptine is a dopamine(DA) agonist as is Pardolel. The DA and Prolactin endocrine connection is where these drugs work. Bromo is currently FDA approved for prolactin induced gyno. Now if you were having negative feedback upon your pituitary as is the situation on a cycle your Prolactin levels would most likely be low, but I have no evidence of that, it is just my medical opinion. in other words you need something that works at the receptors in your breast tissue.
Similar threads
